Ligand Pharmaceuticals (LGND) EBT (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of EBT data on file, last reported at -$24.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 51.66% year-over-year to -$24.3 million; the trailing twelve-month figure through Mar 2026 stood at $184.9 million (up 214.76% YoY), and the FY2025 full-year result was $159.0 million, up 6212.95% from the prior year.
• EBT eased to -$24.3 million in Q1 2026, from $56.8 million in the prior quarter.
• In the past five years, EBT ranged from a high of $141.1 million in Q3 2025 to a low of -$65.4 million in Q2 2024.
• A 5-year average of $13.9 million and a median of $8.7 million in 2022 frame the typical range for EBT.
• Across the five-year window, EBT plunged 2162.13% in 2024 and surged 2326.49% in 2025, its largest moves.
• Tracing LGND's EBT over 5 years: stood at $24.1 million in 2022, then retreated by 29.18% to $17.1 million in 2023, then tumbled by 329.28% to -$39.2 million in 2024, then surged by 244.85% to $56.8 million in 2025, then tumbled by 142.72% to -$24.3 million in 2026.
• Business Quant data shows LGND's EBT at -$24.3 million in Q1 2026, $56.8 million in Q4 2025, and $141.1 million in Q3 2025.